Phase 2 study of MLN8237: Investigational aurora A kinase (aak) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)

Aurora A kinase is essential for cell division (mitotic progression) and is amplified or overexpressed in AML and other blood cancers. An investigational drug, MLN8237 is an orally available, potent, and selective AAK inhibitor. It has shown preclinical activity against leukemia, lymphoma, and myeloma, and clinical activity against treatment-resistant cancers in early-stage human trials.

Read the whole article on Science Daily

More from Science Daily